HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Levine, M. N. Articles by Schulman, S. Search for Related Content PubMed PubMed Citation Articles by Levine, M. N. Articles by Schulman, S.

Hemorrhagic Complications of Anticoagulant Treatment

The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

Correspondence to: Mark N. Levine, MD, MSc, Room 104, First Floor, Henderson Research Centre, 711 Concession St, Hamilton, Ontario L8V 1C3

This chapter about hemorrhagic complications of anticoagulant treatment is part of the seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence Based Guidelines. Bleeding is the major complication of anticoagulant therapy. The criteria for defining the severity of bleeding varies considerably between studies, accounting in part for the variation in the rates of bleeding reported. The major determinants of vitamin K antagonist-induced bleeding are the intensity of the anticoagulant effect, underlying patient characteristics, and the length of therapy. There is good evidence that vitamin K antagonist therapy, targeted international normalized ratio (INR) of 2.5 (range, 2.0 to 3.0), is associated with a lower risk of bleeding than therapy targeted at an INR > 3.0. The risk of bleeding associated with IV unfractionated heparin (UFH) in patients with acute venous thromboembolism (VTE) is < 3% in recent trials. This bleeding risk may increase with increasing heparin dosages and age (> 70 years). Low molecular weight heparin (LMWH) is associated with less major bleeding compared with UFH in acute VTE. UFH and LMWH are not associated with an increase in major bleeding in ischemic coronary syndromes, but are associated with an increase in major bleeding in ischemic stroke. Information on bleeding associated with the newer generation of antithrombotic agents has begun to emerge. In terms of treatment decision making for anticoagulant therapy, bleeding risk cannot be considered alone, ie, the potential decrease in thromboembolism must be balanced against the potential increased bleeding risk.

Key Words: anticoagulant • bleeding • complications • heparin

This article has been cited by other articles:

				C. Kearon, J. S. Ginsberg, J. A. Julian, J. Douketis, S. Solymoss, P. Ockelford, S. Jackson, A. G. Turpie, B. MacKinnon, J. Hirsh, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA, August 23, 2006; 296(8): 935 - 942. [Abstract] [Full Text] [PDF]

				K. Kamohara, K. Fukamachi, Y. Ootaki, M. Akiyama, F. Cingoz, C. Ootaki, D. G. Vince, Z. B. Popovic, M. W. Kopcak Jr, R. Dessoffy, et al. Evaluation of a novel device for left atrial appendage exclusion: The second-generation atrial exclusion device. J. Thorac. Cardiovasc. Surg., August 1, 2006; 132(2): 340 - 346. [Abstract] [Full Text] [PDF]

				G. Hron, M. Kollars, B. R. Binder, S. Eichinger, and P. A. Kyrle Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA, July 26, 2006; 296(4): 397 - 402. [Abstract] [Full Text] [PDF]

				E. Keyurapan, S. J. Hu, M. B. Streiff, L. M. Fayad, and E. G. McFarland Iatrogenic Symptomatic Chest Wall Hematoma After Shoulder Arthroplasty. A Report of Two Cases J. Bone Joint Surg. Am., July 1, 2006; 88(7): 1603 - 1608. [Full Text] [PDF]

				P. de Moerloose, C. M. Samama, and S. Motte Management of venous thromboembolism: [Traitement de la maladie thromboembolique veineuse]. Can J Anesth, June 1, 2006; 53(6_suppl): S80 - S88. [Abstract] [Full Text] [PDF]

				K. Kamohara, K. Fukamachi, Y. Ootaki, M. Akiyama, F. Zahr, M. W. Kopcak Jr, R. Dessoffy, Z. B. Popovic, M. Daimon, D. M. Cosgrove, et al. A novel device for left atrial appendage exclusion J. Thorac. Cardiovasc. Surg., December 1, 2005; 130(6): 1639 - 1644. [Abstract] [Full Text] [PDF]

				R. A. Wilke, R. L. Berg, H. J. Vidaillet, M. D. Caldwell, J. K. Burmester, and M. A. Hillman Impact of Age, CYP2C9 Genotype and Concomitant Medication on the Rate of Rise for Prothrombin Time During the First 30 Days of Warfarin Therapy Clin. Med. Res., November 1, 2005; 3(4): 207 - 213. [Abstract] [Full Text] [PDF]

				M. C. Fang, D. E. Singer, Y. Chang, E. M. Hylek, L. E. Henault, N. G. Jensvold, and A. S. Go Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study Circulation, September 20, 2005; 112(12): 1687 - 1691. [Abstract] [Full Text] [PDF]

				D. Aujesky, K. J. Smith, J. Cornuz, and M. S. Roberts Cost-Effectiveness of Low-Molecular-Weight Heparin for Treatment of Pulmonary Embolism Chest, September 1, 2005; 128(3): 1601 - 1610. [Abstract] [Full Text] [PDF]

				D. Ost, J. Tepper, H. Mihara, O. Lander, R. Heinzer, and A. Fein Duration of Anticoagulation Following Venous Thromboembolism: A Meta-analysis JAMA, August 10, 2005; 294(6): 706 - 715. [Abstract] [Full Text] [PDF]

				M. H. Eckman "Bridging On the River Kwai": The Perioperative Management of Anticoagulation Therapy Med Decis Making, July 1, 2005; 25(4): 370 - 373. [PDF]

				P. S.J. Miller, M. F. Drummond, L. K. Langkilde, J. J.V. McMurray, and M. Ogren Economic factors associated with antithrombotic treatments for stroke prevention in patients with atrial fibrillation Eur. Heart J. Suppl., May 1, 2005; 7(suppl_C): C41 - C54. [Abstract] [Full Text] [PDF]